TSC22D3 and lung carcinoma: Our findings demonstrate that RBM47-ISGylation inhibits the expression of TSC22D3 in human cells, including lung cancer cell lines and the T lymphocyte line Jurkat, demonstrating that human RBM47-ISGylation has a consistent function, as confirmed by mouse models.